Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | UBE2N | P61088 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532250 | 0.76 | MAPT (0.58) | RECQLLMNAMAPTATMGAA | |
| SCHEMBL13467800 | 0.75 | L3MBTL1 (0.80) | LMNASMN1; SMN2RXFP1MAPTL3MBTL1 | |
| SCHEMBL24209796 | 0.72 | MAPT (0.67) | LMNASMN1; SMN2RXFP1MAPTGPR35 | |
| SCHEMBL25482008 | 0.72 | L3MBTL1 (0.78) | LMNARXFP1MAPTGAAL3MBTL1 | |
| SCHEMBL13451645 | 0.71 | L3MBTL1 (0.73) | LMNASMN1; SMN2RXFP1MAPTL3MBTL1 | |
| SCHEMBL14399027 | 0.71 | RECQL (0.57) | RECQLLMNASMN1; SMN2RXFP1MAPT | |
| SCHEMBL25482034 | 0.71 | ALDH1A1 (0.82) | LMNARXFP1MAPTGAAALDH1A1 | |
| SCHEMBL25482016 | 0.69 | LMNA (0.82) | LMNASMN1; SMN2L3MBTL1ALDH1A1HPGD | |
| SCHEMBL13831486 | 0.69 | MAPT (0.73) | LMNASMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL4210220 | 0.69 | TSHR (0.82) | SMN1; SMN2MAPTGAAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-09 | — | — | US | disclosed |
| US-8969342-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20120264760-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264760-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | University of Georgia Foundation, Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20100022547-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections | BRANDEIS UNIVERSITY (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022547-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections | BRANDEIS UNIVERSITY (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2007143557-A2 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL PARASITIC INFECTIONS | BRANDEIS UNIVERSITY (US) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | RECQL 1610/4885LMNA 3978/4885SMN1; SMN2 4251/4885 |
| US-20120264760-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections | IMPDH1, IMPDH2, ITPA | RECQL 1266/4885LMNA 3931/4885SMN1; SMN2 3305/4885 |
| US-20100022547-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections | IMPDH1, IMPDH2, ITPA | RECQL 1266/4885LMNA 3931/4885SMN1; SMN2 3305/4885 |
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | RECQL 1610/4885LMNA 3978/4885SMN1; SMN2 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.